The Oncology Institute Announces Resignation of Board Member Gabe Ling

Rhea-AI Summary

The Oncology Institute (NASDAQ: TOI) announced that Gabe Ling resigned from the Board of Directors, effective December 1, 2025. The company said a formal search has begun to add independent directors with healthcare, clinical, and value-based care expertise.

The board emphasized thanks for Ling’s service during the company’s early public-market years and stated a continuing focus on strengthening governance and recruiting strategic, experienced members to support long-term growth.

Positive

• Board member resignation effective December 1, 2025
• Formal search initiated for independent directors with clinical expertise

Negative

• No timeline provided for replacement of the vacant board seat

CERRITOS, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced that Gabe Ling has resigned from the Board of Directors, effective December 1, 2025. A formal search process has been initiated to add new independent directors with complementary healthcare, clinical, and value-based care expertise.

“On behalf of the Board of Directors, I want to thank Gabe for his service during an important chapter in The Oncology Institute’s development,” said Anne McGeorge, Chairman of the Board. “We appreciate the contributions he made throughout his time on the Board and the valuable guidance he provided as the Company navigated its first few years in the public markets. As we continue to strengthen our governance structure, we remain focused on enhancing the Board’s capabilities by bringing on strategic and experienced members who will support The Oncology Institute’s mission and long-term growth goals.”

About The Oncology Institute
Founded in 2007, The Oncology Institute (NASDAQ: TOI) is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of approximately 1.9 million patients, including clinical trials, transfusions, and other care delivery models traditionally associated with the most advanced care delivery organizations. With over 180 employed and affiliate clinicians and over 100 clinics and affiliate locations of care across five states and growing, TOI is changing oncology for the better. For more information, visit www.theoncologyinstitute.com

Contacts

Media

The Oncology Institute, Inc.
marketing@theoncologyinstitute.com

Investors

ICR Healthcare
TOI@icrhealthcare.com

FAQ

Who resigned from The Oncology Institute board effective December 1, 2025 (TOI)?

Gabe Ling resigned from the Board of Directors, effective December 1, 2025.

What steps is The Oncology Institute (TOI) taking after Gabe Ling's resignation?

The company has initiated a formal search to add independent directors with healthcare, clinical, and value-based care expertise.

How will Gabe Ling's resignation affect The Oncology Institute's governance (TOI)?

The board said it is focused on strengthening governance by recruiting strategic, experienced directors to support long-term growth.

Does The Oncology Institute (TOI) provide a timeline for appointing new directors?

No timeline for appointments was provided in the announcement.

Who commented on Gabe Ling’s resignation from The Oncology Institute (TOI)?

Anne McGeorge, Chairman of the Board, thanked Gabe Ling for his service and guidance during the company’s early public years.